Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation., Genentech, Lilly, Pfizer, Merck Sharp & Dohme Corp, and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com

Community Practice Connections™: 16th Annual Winter Lung Cancer Conference


Release Date: March 29, 2019
Expiration Date: March 29, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: 16th Annual Winter Lung Cancer Conference consists of a series of interactive clinical vignettes, short video interviews of leading experts in lung cancer, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

CME Activity Table of Contents

  • Module 1. Oncogene-Driven NSCLC
  • Module 2: Unresectable Stage III NSCLC
  • Module 3: Immunotherapy in Metastatic NSCLC
  • Module 4: Small Cell Lung Cancer

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation., Genentech, Lilly, Pfizer, Merck Sharp & Dohme Corp, and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/Ce certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed toward oncologists involved in the treatment and management of patients with lung cancers. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of lung cancers may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Incorporate molecular testing strategies to inform treatment selection in patients with oncogene-driven NSCLC
  • Discuss emerging approaches for patient selection for immunotherapy and targeted agents
  • Evaluate treatment strategies for early-stage and locally advanced lung cancer
  • Discuss the use of cytotoxic, targeted, and other systemic agents in the management of patients with lung cancer with or without oncogenic drivers
  • Apply immunotherapeutic strategies in patients with thoracic malignancies along the disease continuum
  • Explain approaches to mitigate and manage treatment-related adverse events in patients with lung cancer

Faculty, Staff, and Planners’ Disclosures

Julie R. Brahmer
Julie R. Brahmer, MD, MSc, FASCO
Director, Thoracic Oncology Program
Kimmel Cancer Center at Johns Hopkins Bayview
Professor of Oncology
Johns Hopkins Kimmel Cancer Center
Baltimore, MD

Disclosures: Grant/Research Support: Bristol-Myers Squibb, MedImmune/AstraZeneca, Merck; Consultant: Bristol-Myers Squibb (uncompensated), Celgene, Lilly, Merck, Genentech, Amgen, Syndax.

Rogerio C. Lilenbaum
Rogerio C. Lilenbaum, MD
Professor of Medicine in Medical Oncology
Chief Medical Officer of Smilow Cancer Hospital – Yale New Haven Health
New Haven, CT

Disclosures: Consultant: AstraZeneca.

Mark A. Socinski
Mark A. Socinski, MD
Executive Medical Director
Florida Hospital Cancer Institute
Orlando, FL

Disclosures: No relevant financial relationships with commercial interests.

Heather A. Wakelee
Heather A. Wakelee, MD
Professor of Medicine (Oncology)
Stanford University Medical Center
Stanford, CA

Disclosures: Grant/Research Support: Genentech/Roche, Pfizer, Lilly, Celgene, AstraZeneca/MedImmune, Exelixis, Novartis, Clovis Oncology, Xcovery, Bristol-Myers Squibb, Gilead, Pharmacyclics, ACEA Biosciences, Merck; Consultant: AstraZeneca, Novartis, Genentech/Roche (unpaid); Other: Steering Committee Participation/Unpaid Advisor: Genentech/Roche, Merck, Novartis, AstraZeneca, Arys, Cellworks, Clovis Oncology.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI. Additionally, PER® is required by the ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By